Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18576422 | 1.00 | PIK3CD (0.37) | PIK3CDP2RX7KMT2A | |
| SCHEMBL13329931 | 1.00 | PIK3CD (0.37) | PIK3CDP2RX7KMT2A | |
| SCHEMBL22114509 | 0.89 | PIK3CD (0.39) | PIK3CDP2RX7KMT2A | |
| SCHEMBL2035159 | 0.82 | P2RX7 (0.35) | P2RX7KMT2A | |
| SCHEMBL19686585 | 0.79 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL22833695 | 0.77 | TSHR (0.42) | PIK3CD | |
| SCHEMBL19186458 | 0.76 | CHRM2 (0.34) | P2RX7KMT2A | |
| SCHEMBL24434648 | 0.74 | TP53 (0.50) | — | |
| SCHEMBL22833713 | 0.74 | TP53 (0.46) | KMT2A | |
| SCHEMBL27112747 | 0.73 | P2RX7 (0.35) | P2RX7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | PIK3CD 1813/4885P2RX7 1316/4885KMT2A 2306/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PIK3CD 1022/4885P2RX7 2488/4885KMT2A 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.